Biomea Fusion presents COVALENT-111 study results at WCIRDC

Biomea Fusion (BMEA) announced that it presented COVALENT-111 study results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, WCIRDC, which took place December 3-6, 2025 in Los Angeles, California. The data showed durable glycemic and c-peptide improvements with icovamenib, a menin inhibitor targeting beta-cell restoration in insulin deficient type 2 diabetes. Key Highlights from WCIRDC showing HbA1c and C-peptide responses at week 52 – 9 months post the last dose: Icovamenib demonstrated durable and continuous treatment effect in severe insulin-deficient type 2 diabetes; Higher HbA1c reduction was associated with higher icovamenib exposure; Icovamenib improved long-term insulin secretion in severe insulin-deficient T2D; Treatment effect in GLP-1 “failures” continued to improve with durable and clinically significant improvements in HbA1c; Icovamenib was generally well-tolerated, with no adverse-event related discontinuations and no related serious adverse events